155 filings
Page 3 of 8
8-K
p9xfxusv
27 Jun 22
Regulation FD Disclosure
4:25pm
8-K
hxs3cly
16 Jun 22
Submission of Matters to a Vote of Security Holders
4:29pm
8-K
7oqt103pbxtfs7r
13 May 22
Departure of Directors or Certain Officers
4:56pm
8-K
lhcxx9
12 May 22
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
4:08pm
8-K
f9g bmjslx3y4
3 May 22
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
4:08pm
DEFA14A
nu854w
26 Apr 22
Additional proxy soliciting materials
4:32pm
S-8
gucsvp
17 Mar 22
Registration of securities for employees
5:06pm
8-K
kw6bb9
17 Mar 22
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
4:05pm
8-K
s0q6 2gvo
7 Jan 22
Results of Operations and Financial Condition
5:00pm
8-K
j83mpcnbu
20 Dec 21
Termination of a Material Definitive Agreement
5:21pm
S-3ASR
gmq59r5
20 Dec 21
Automatic shelf registration
5:01pm
8-K
z5000ifnehuq3f
10 Dec 21
Departure of Directors or Certain Officers
4:10pm
8-K
ktqhbut36l cshr4m5
19 Nov 21
Entry into a Material Definitive Agreement
6:08am
424B5
dgvc1 95oi54br3o
19 Nov 21
Prospectus supplement for primary offering
6:05am
8-K
qs49a1cgzpk r3gqkxs
15 Nov 21
Regulation FD Disclosure
4:23pm
8-K
o3l 7uha9n5m
9 Nov 21
Kezar Reports Third Quarter Financial Results and Provides Business Update
4:10pm